Merrion Announces Company's Latest Oral Drug Delivery Patent

Merrion Pharmaceuticals, Inc., a specialty pharmaceutical company with novel approaches to oral drug delivery, is pleased to announce the issue of European Patent Number EP1131344, "Retro-inversion peptides that target gastro-intestinal tract transport receptors and related methods." This patent further expands Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) technology base, and covers targeting peptides that enhance oral drug delivery by specifically binding to gastrointestinal tract transport receptors.

Yahoo News (http://biz.yahoo.com/bw/050330/305022.html?.v=1)